MR
MRK.F Merck & Company Inc
- Market cap
- EUR 64.3B
- P/E
- 27.1x
- P/B
- 2.18x
- ROE
- 7.6%
- Dividend yield
- 0.44%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MRK.F undervalued?
Graham numberMRK.F trades 62.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Merck & Company Inc fundamental analysis
No fundamental analysis for Merck & Company Inc yet.
Merck & Company Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Merck & Company Inc
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomo…
Full company profileMerck & Company Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Merck & Company Inc annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.0B | 15.3B | 14.8B | 16.2B | 17.5B | 19.7B | 22.2B | 21.0B | 21.2B | 21.1B | 21.1B |
| Gross Profit | 9.82B | 10.0B | 9.45B | 10.1B | 10.5B | 12.3B | 13.7B | 12.4B | 12.5B | 12.3B | 12.5B |
| Operating Income | 1.89B | 1.71B | 1.37B | 1.68B | 2.81B | 4.20B | 4.75B | 3.57B | 4.01B | 3.66B | 3.38B |
| EBITDA | - | 4.33B | 3.61B | 4.16B | 4.96B | 5.96B | 6.55B | 5.69B | 5.96B | 5.99B | 5.62B |
| Net Income | 1.63B | 2.60B | 3.37B | 1.32B | 1.99B | 3.06B | 3.33B | 2.82B | 2.78B | 2.61B | 2.30B |
| EPS | - | 5.98 | 7.76 | 3.04 | 4.57 | 7.03 | 7.65 | 6.50 | 6.39 | 6.00 | 5.29 |
| Balance Sheet | |||||||||||
| Total Assets | 38.3B | 35.6B | 36.9B | 43.8B | 41.8B | 45.4B | 48.5B | 48.5B | 51.6B | 51.5B | 52.7B |
| Total Liabilities | 24.2B | 21.6B | 19.7B | 25.9B | 24.8B | 23.9B | 22.5B | 21.7B | 21.6B | 22.9B | 22.4B |
| Shareholders' Equity | 14.0B | 14.0B | 17.2B | 17.9B | 16.9B | 21.3B | 25.9B | 26.7B | 29.9B | 28.6B | 30.2B |
| Cash & Short-term Investments | 939M | 589M | 2.17B | 541M | 1.11B | 1.51B | 1.40B | 1.58B | 2.15B | 2.33B | 1.96B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.52B | 2.70B | 2.22B | 2.86B | 3.48B | 4.62B | 4.26B | 3.78B | 4.59B | 3.93B | 2.85B |
| Capital Expenditure | 848M | 919M | 910M | 813M | 1.41B | 1.07B | 1.53B | 2.02B | 2.18B | 1.96B | 1.73B |
| Free Cash Flow | - | 1.39B | 1.20B | 1.84B | 1.91B | 3.20B | 2.45B | 1.76B | 2.40B | 1.97B | 1.11B |
| Ratios | |||||||||||
| ROE | 11.6% | 18.6% | 19.6% | 7.4% | 11.7% | 14.3% | 12.8% | 10.6% | 9.3% | 9.1% | 7.6% |
| ROA | 4.3% | 7.3% | 9.1% | 3.0% | 4.8% | 6.7% | 6.9% | 5.8% | 5.4% | 5.1% | 4.4% |
| Net Profit Margin | 10.8% | 17.0% | 22.7% | 8.2% | 11.3% | 15.5% | 15.0% | 13.5% | 13.1% | 12.4% | 10.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Merck & Company Inc dividends
- Dividend yield
- 0.44%
- Forward dividend
- 2.20 EUR
- Payout ratio
- 10.9%
- Ex-dividend date
- Apr 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 284M | 0.65 | 10.9% |
| 2024 | EUR 284M | 0.65 | 10.2% |
| 2023 | EUR 284M | 0.65 | 10.1% |
| 2022 | EUR 955M | 2.20 | 28.7% |
| 2021 | EUR 748M | 1.72 | 24.5% |
| 2020 | EUR 680M | 1.56 | 34.2% |
| 2019 | EUR 677M | 1.56 | 51.3% |
| 2018 | EUR 755M | 1.74 | 22.4% |
| 2017 | EUR 621M | 1.43 | 23.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 30, 2014.
Who owns Merck & Company Inc
- Insiders 0.00%
- Institutions 60.75%
- Public & others 39.25%
- Shares outstanding 129M
- Free float 129M
Merck & Company Inc company profile
- Company name
- Merck & Company Inc
- Ticker
- MRK.F
- ISIN
- DE0006599905
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 62,136
- Fiscal year end
- December
- Address
- Frankfurter Strasse 250, Darmstadt, Germany, 64293
- Phone
- 49 6151 72 0
- Website
- merckgroup.com
About Merck & Company Inc
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a sub
Merck & Company Inc management
10- Dr. Kai BeckmannCEO & Chair of Management Board · born 1965
- Ms. Helene von RoederCFO & Member of Executive Board · born 1970
- Mr. Danny Pinhas Bar-Zohar M.D.Member of the Executive Board & CEO of Healthcare · born 1970
- Mr. Jean Charles WirthMember of the Executive Board & CEO Life Science · born 1973
- Ms. Khadija Ben HammadaMember of the Executive Board & Chief People Officer · born 1980
- Mr. Benjamin HeinMember of Management Board & CEO of Electronics Business Sector
- Florian SchraederHead of Investor Relations
- Mr. Axel LoberHead of Global Communications
- Mr. Frank GotthardtHead of Corporate & Government Relations - Europe
- Mr. Marc HornHead of Life Science Controlling · born 1975